Deepak Builders secures Rs 142.6 crore Unity Mall project in Karnal
Deepak Builders has officially received the Letter of Acceptance (LoA) from the Haryana State Industrial & Infrastructure Development Corporation (HSIIDC) for the construction of Unity Mall at Sector-37, HSIIDC Industrial Estate, Karnal.
This development follows the company's earlier announcement on June 3, 2025, where it emerged as the L1 (lowest) bidder for the Engineering, Procurement, and Construction (EPC) contract. The project includes comprehensive planning, design, engineering, procurement, and construction work, along with all other related components.
The total construction cost of the project is pegged at ₹142.60 crore (including GST), while the base contract value stands at ₹120.85 crore (excluding GST).
The Unity Mall project is expected to be completed within 24 months from the date of commencement. Additionally, there will be a 36-month defect liability period and a 12-month operations and maintenance (O&M) phase thereafter.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
V2 Retail Q1 FY26 business update: Company reports 51% YoY revenue growth, adds 28 new stores
V2 Retail Limited has reported a strong start to FY26, delivering impressive growth in its Q1 business update. The company's standalone revenue surged to ₹628 crore in Q1 FY26, marking a 51% year-on-year jump from ₹415 crore in Q1 FY25. This performance highlights the success of its product-first approach, robust sell-through rates, and deeper market reach. Same-store sales growth (SSSG) normalized at 10%, despite an early Eid impact in April. May and June recorded strong double-digit growth, reflecting steady consumer demand and smart assortment planning. Sales per square foot for Q1 stood at ₹957, showing solid store-level productivity—even with a higher contribution from new stores. This was made possible through improved merchandising, faster stock replenishments, and strict inventory control. V2 Retail also expanded its footprint by opening 28 new stores during the quarter while closing one underperforming outlet. The total store count now stands at 216, covering a retail area of 23.48 lakh sq. ft. The company continues to focus on Tier 2 and Tier 3 cities, strengthening its mission to bring affordable fashion to emerging India. The company emphasized its strong momentum going into FY26, driven by innovation, data-backed merchandising, and customer trust. With an expanding footprint and a clear focus on value fashion, V2 Retail is well-positioned to lead in India's fast-evolving retail landscape. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Aurobindo Pharma's subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys'
Aurobindo Pharma's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzumab biosimilar. This approval follows the positive opinion issued by the European Medicines Agency's (EMA) CHMP in April 2025, recommending the product for authorization. Dazublys™ is a biosimilar of trastuzumab, a widely used monoclonal antibody in the treatment of HER2-positive breast and gastric cancers. With this latest approval, Dazublys™ becomes CuraTeQ's third EMA-approved biosimilar, following Dyrupeg™ (approved in April 2025) and Zefylti™ (approved in February 2025). It also marks the fourth biosimilar approval for CuraTeQ in the European region, including Bevqolva™, which received a green light from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in December 2024. This continued string of regulatory successes further strengthens Aurobindo Pharma's global biosimilar portfolio and underscores the company's commitment to expanding access to high-quality, affordable biologics in key regulated markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
5 hours ago
- Business Upturn
Stocks hitting 52-week highs today, July 2: Divi's Laboratories, Bharti Airtel, UltraTech Cement, Dalmia Bharat and more
By Aman Shukla Published on July 2, 2025, 15:45 IST Despite broader market weakness on July 2, several stocks managed to hit their 52-week highs, signalling strong investor interest. The Sensex slipped 287.60 points to close at 83,409.69, while the Nifty ended 88.40 points lower at 25,453.40. However, the following stocks stood out by touching fresh 52-week highs during the session. Key Stocks That Hit 52-Week Highs Today (July 2) Company Market Price (₹) 52-Week High (₹) Divi's Laboratories 6,859.50 (+0.04%) 6,885.50 Bharti Airtel 2,033.30 (+0.69%) 2,045.80 Laurus Labs 756.75 (+1.43%) 761.75 UltraTech Cement 12,436.00 (+1.85%) 12,527.00 SRF 3,255.60 (+1.74%) 3,281.60 JK Lakshmi Cement 986.00 (+3.56%) 995.00 Federal Bank 217.75 (-0.44%) 220.00 LT Foods 494.75 (+3.95%) 500.00 Dalmia Bharat 2,220.10 (+1.43%) 2,245.00 Ramco Cements 1,088.40 (+1.04%) 1,101.90 Asahi India Glass 830.55 (+3.01%) 842.00 L&T Finance 206.22 (-0.78%) 209.60 AU Small Finance Bank 818.25 (-2.40%) 841.00 KRBL 379.50 (+1.12%) 390.40 Gabriel India 976.20 (+15.84%) 1,011.30 Cholamandalam Financial Holdings 2,148.80 (+1.74%) 2,231.60 South Indian Bank 31.04 (-1.77%) 32.25 Fiem Industries 1,923.30 (-0.77%) 1,999.00 City Union Bank 221.44 (-3.93%) 232.55 Sai Life Sciences 789.10 (+1.19%) 838.50 Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Bharti AirtelDalmia BharatDivi's LaboratoriesStock MarketUltraTech Cement Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
